NKGen Biotech, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 5.38 million compared to USD 8.32 million a year ago. Basic loss per share from continuing operations was USD 0.25 compared to USD 0.63 a year ago.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1.19 USD | 0.00% |
|
0.00% | -56.73% |
1st Jan change | Capi. | |
---|---|---|
-56.73% | 29.62M | |
+25.89% | 52.73B | |
+37.49% | 39B | |
-9.37% | 38.52B | |
+29.54% | 30.38B | |
-12.26% | 26.39B | |
+10.95% | 26.08B | |
+45.07% | 14.15B | |
+32.45% | 12.6B | |
-5.74% | 11.51B |
- Stock Market
- Equities
- NKGN Stock
- News NKGen Biotech, Inc.
- NKGen Biotech, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024